138 related articles for article (PubMed ID: 25702050)
1. Amrubicin monotherapy for patients with extrapulmonary neuroendocrine carcinoma after platinum-based chemotherapy.
Nio K; Arita S; Isobe T; Kusaba H; Kohashi K; Kajitani T; Tamura S; Hirano G; Mitsugi K; Makiyama A; Esaki T; Ariyama H; Oda Y; Akashi K; Baba E
Cancer Chemother Pharmacol; 2015 Apr; 75(4):829-35. PubMed ID: 25702050
[TBL] [Abstract][Full Text] [Related]
2. [Efficacy of Amrubicin Monotherapy for Patients with Extrapulmonary Neuroendocrine Carcinomas Refractory to Platinum-Based Chemotherapy].
Funasaka C; Kanemasa Y; Kageyama A; Shimoyama T; Omuro Y
Gan To Kagaku Ryoho; 2020 Aug; 47(8):1205-1208. PubMed ID: 32829355
[TBL] [Abstract][Full Text] [Related]
3. Amrubicin Monotherapy for Patients with Platinum-Pretreated Non-Gastrointestinal Non-Pancreatic Extrapulmonary Neuroendocrine Carcinoma.
Ebata T; Shimoi T; Ishiwata T; Iwasawa S; Bun S; Yunokawa M; Yonemori K; Takiguchi Y; Tamura K
Oncology; 2017; 93(3):177-182. PubMed ID: 28521313
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of amrubicin and carboplatin in patients with sensitive or refractory relapsed small-cell lung cancer.
Hirose T; Nakashima M; Shirai T; Kusumoto S; Sugiyama T; Yamaoka T; Okuda K; Ohnishi T; Ohmori T; Adachi M
Lung Cancer; 2011 Sep; 73(3):345-50. PubMed ID: 21277039
[TBL] [Abstract][Full Text] [Related]
5. Cervical non-squamous carcinoma: an effective combination chemotherapy of taxane, anthracycline and platinum for advanced or recurrent cases.
Kimura T; Miyatake T; Ueda Y; Ohta Y; Enomoto T; Kimura T; Kamiura S
Eur J Obstet Gynecol Reprod Biol; 2012 Oct; 164(2):200-4. PubMed ID: 22770633
[TBL] [Abstract][Full Text] [Related]
6. Randomized phase II trial comparing amrubicin with re-challenge of platinum doublet in patients with sensitive-relapsed small-cell lung cancer: North Japan Lung Cancer Study Group trial 0702.
Inoue A; Sugawara S; Maemondo M; Mori Y; Oizumi S; Harada M; Taima K; Morikawa N; Ishida T; Kinoshita I; Watanabe H; Suzuki T; Nakagawa T; Saito R; Nukiwa T
Lung Cancer; 2015 Jul; 89(1):61-5. PubMed ID: 26004087
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcome of amrubicin therapy according to the prior chemotherapy sensitivities of extensive small cell lung cancer.
Mitsuoka S; Kudoh S; Kimura T; Yoshimura N; Tanaka H; Suzumura T; Umekawa K; Nagata M; Ueda T; Hirata K
Osaka City Med J; 2011 Dec; 57(2):59-66. PubMed ID: 22443079
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of Platinum-Based Chemotherapy for Relapsed Small-Cell Lung Cancer after Amrubicin Monotherapy in Elderly Patients and Patients with Poor Performance Status.
Igawa S; Shirasawa M; Fukui T; Nishinarita N; Sone H; Ozawa T; Sugita K; Okuma Y; Kurahayashi S; Ono T; Sugimoto A; Mitsufuji H; Kubota M; Katagiri M; Sasaki J; Naoki K
Oncology; 2018; 94(4):207-214. PubMed ID: 29393275
[TBL] [Abstract][Full Text] [Related]
9. Cisplatin and etoposide as first-line chemotherapy for poorly differentiated neuroendocrine carcinoma of the hepatobiliary tract and pancreas.
Iwasa S; Morizane C; Okusaka T; Ueno H; Ikeda M; Kondo S; Tanaka T; Nakachi K; Mitsunaga S; Kojima Y; Hagihara A; Hiraoka N
Jpn J Clin Oncol; 2010 Apr; 40(4):313-8. PubMed ID: 20047862
[TBL] [Abstract][Full Text] [Related]
10. A single-arm confirmatory study of amrubicin therapy in patients with refractory small-cell lung cancer: Japan Clinical Oncology Group Study (JCOG0901).
Murakami H; Yamamoto N; Shibata T; Takeda K; Ichinose Y; Ohe Y; Yamamoto N; Takeda Y; Kudoh S; Atagi S; Satouchi M; Kiura K; Nogami N; Endo M; Watanabe H; Tamura T
Lung Cancer; 2014 Apr; 84(1):67-72. PubMed ID: 24530204
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of Second-Line Chemotherapy in Extrapulmonary Neuroendocrine Carcinoma.
McGarrah PW; Leventakos K; Hobday TJ; Molina JR; Finnes HD; Westin GF; Halfdanarson TR
Pancreas; 2020 Apr; 49(4):529-533. PubMed ID: 32282766
[TBL] [Abstract][Full Text] [Related]
12. Amrubicin for the treatment of neuroendocrine carcinoma of the gastrointestinal tract: a retrospective analysis of five cases.
Asayama M; Fuse N; Yoshino T; Yano T; Tahara M; Doi T; Fujii S; Ohtsu A
Cancer Chemother Pharmacol; 2011 Nov; 68(5):1325-30. PubMed ID: 21461890
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of amrubicin monotherapy in patients with platinum-refractory metastatic neuroendocrine carcinoma of the gastrointestinal tract: a single cancer center retrospective study.
Kitagawa Y; Osumi H; Shinozaki E; Ota Y; Nakayama I; Suzuki T; Wakatsuki T; Ichimura T; Ogura M; Ooki A; Takahari D; Suenaga M; Chin K; Yamaguchi K
Cancer Manag Res; 2019; 11():5757-5764. PubMed ID: 31417315
[TBL] [Abstract][Full Text] [Related]
14. Amrubicin in patients with platinum-refractory metastatic neuroendocrine carcinoma and mixed adenoneuroendocrine carcinoma of the gastrointestinal tract.
Araki T; Takashima A; Hamaguchi T; Honma Y; Iwasa S; Okita N; Kato K; Yamada Y; Hashimoto H; Taniguchi H; Kushima R; Nakao K; Boku N; Shimada Y
Anticancer Drugs; 2016 Sep; 27(8):794-9. PubMed ID: 27341105
[TBL] [Abstract][Full Text] [Related]
15. A phase II study of amrubicin and carboplatin for previously untreated patients with extensive-disease small cell lung cancer.
Ikeda T; Fukuda M; Nakamura Y; Kinoshita A; Senju H; Nakano H; Kitazaki T; Ogawara D; Taniguchi H; Motoshima K; Yamaguchi H; Nakatomi K; Shimada M; Nagashima S; Tsukamoto K; Kohno S;
Cancer Chemother Pharmacol; 2014 Sep; 74(3):497-502. PubMed ID: 25034978
[TBL] [Abstract][Full Text] [Related]
16. Good performance of platinum-based chemotherapy for high-grade gastroenteropancreatic and unknown primary neuroendocrine neoplasms.
Brandi G; Paragona M; Campana D; Brighi N; Bondi A; Pantaleo MA; Corbelli J; Barbera MA; Biasco G
J Chemother; 2018 Feb; 30(1):53-58. PubMed ID: 28641483
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer.
Ettinger DS; Jotte R; Lorigan P; Gupta V; Garbo L; Alemany C; Conkling P; Spigel DR; Dudek AZ; Shah C; Salgia R; McNally R; Renschler MF; Oliver JW
J Clin Oncol; 2010 May; 28(15):2598-603. PubMed ID: 20385980
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of Amrubicin combined with carboplatin for thymic carcinoma and invasive thymoma: North Japan Lung Cancer group study 0803.
Inoue A; Sugawara S; Harada M; Kobayashi K; Kozuki T; Kuyama S; Maemondo M; Asahina H; Hisamoto A; Nakagawa T; Hotta K; Nukiwa T
J Thorac Oncol; 2014 Dec; 9(12):1805-9. PubMed ID: 25393793
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of temozolomide monotherapy in patients with extrapulmonary neuroendocrine carcinoma.
Kobayashi N; Takeda Y; Okubo N; Suzuki A; Tokuhisa M; Hiroshima Y; Ichikawa Y
Cancer Sci; 2021 May; 112(5):1936-1942. PubMed ID: 33453146
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Carboplatin and Etoposide Combination Chemotherapy for Extrapulmonary Neuroendocrine Carcinoma: A Retrospective Case Series.
Imai H; Shirota H; Okita A; Komine K; Saijo K; Takahashi M; Takahashi S; Takahashi M; Shimodaira H; Ishioka C
Chemotherapy; 2016; 61(3):111-6. PubMed ID: 26636658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]